1405 GMT - Bayer's new stroke drug looks well positioned to withstand competition, according to analysts at Bank of America. The drug asundexian is likely to benefit from good adoption and could generate annual sales of 3 billion euros at its peak, the bank estimates. Rivals Bristol Myers Squibb and Johnson & Johnson are working together on a competitor medicine candidate, milvexian. Upcoming data on milvexian could prompt Bank of America to revise its asundexian estimate, but most scenarios it is contemplating would result in upgrades. Even if milvexian ends up working in secondary stroke prevention and stroke prevention in atrial fibrillation, consensus estimates for asundexian peak sales of 2 billion euros would face limited risk, the analysts say. Bayer shares rise 0.2%.